Breaking Finance News

DaVita HealthCare Partners Inc (NYSE:DVA) has been upgraded from Market Perform to Outperform in a report by Raymond James today.

Just yesterday DaVita HealthCare Partners Inc (NYSE:DVA) traded 0.00% even at $63.60. DaVita HealthCare Partners Inc’s 50-day moving average is $67.46 and its 200-day moving average is $73.22. The last closing price is down -13.14% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 3,747 shares of the stock traded hands, down from an average trading volume of 1,506,600

Raymond James has upgraded DaVita HealthCare Partners Inc (NYSE:DVA) from Market Perform to Outperform in a report released on 9/20/2016.

See Chart Below

DaVita HealthCare Partners Inc (NYSE:DVA)

DaVita HealthCare Partners Inc has a 52 week low of $61.36 and a 52 week high of $78.94 with a PE ratio of 37 DaVita HealthCare Partners Inc’s market capitalization is presently $0.

A total of 9 analysts have released a report on DaVita HealthCare Partners Inc. 4 firms rating the stock a strong buy, 1 firm rating the stock a buy, 7 firms rating the stock a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $77.00.

Brief Synopsis About DaVita HealthCare Partners Inc (NYSE:DVA)

DaVita Inc., formerly DaVita HealthCare Partners Inc., is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company's segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. The Company's Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). HCP division is a patient and physician-focused integrated health care delivery and management company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *